Helicobacter pylori research: Historical insights and future directions

Nature Reviews Gastroenterology and Hepatology

Volumn 10, Issue 8, 2013, Pages 495-500

  Fock, Kwong Ming ^a   Graham, David Y ^b   Malfertheiner, Peter ^c  

^a CHANGI GENERAL HOSPITAL   (Singapore)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Otto von Guericke Universtität ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BISMUTH DERIVATIVE; CLARITHROMYCIN; HELICOBACTER PYLORI VACCINE; LEVOFLOXACIN; METRONIDAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL VIRULENCE; CANCER RISK; CHRONIC GASTRITIS; COMBINATION CHEMOTHERAPY; DEVELOPING COUNTRY; DISEASE ASSOCIATION; DUODENUM ULCER; ERADICATION THERAPY; GASTRITIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INTESTINE FLORA; MARGINAL ZONE LYMPHOMA; NONHUMAN; PEPTIC ULCER; PREVALENCE; PRIORITY JOURNAL; REVIEW; STOMACH ATROPHY; STOMACH CANCER;

ANTI-BACTERIAL AGENTS; CHRONIC DISEASE; DRUG RESISTANCE, BACTERIAL; GASTRITIS; GASTROENTEROLOGY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MICROBIOLOGICAL TECHNIQUES; MICROBIOTA; PEPTIC ULCER;

EID: 84881475256     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2013.96     Document Type: Review

References (45)

1. [No authors listed] Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the evaluation of carcinogenic risks to humans. Lyon, 7-14 June 1994. IARC Monogr. Eval. Carcinog. Risks Hum. 61, 1-241 (1994).
2. Parkin, D. M. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 118, 3030-3044 (2006).
3. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 49, 347-353 (2001).
4. Fock, K. M. et al. Asia-Pacific consensus guidelines on gastric cancer prevention. J. Gastroenterol. Hepatol. 23, 351-365 (2008).
5. Lee, Y. C. et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut 62, 676-682 (2013).
6. Graham, D. Y. & Asaka, M. Eradication of gastric cancer and more efficient gastric cancer surveillance in Japan: two peas in a pod. J. Gastroenterol. 45, 1-8 (2010).
7. Comfort, M. W. Gastric acidity before and after development of gastric cancer: its etiologic, diagnostic and prognostic significance. Ann. Intern. Med. 36, 1331-1348 (1951).
8. Cotton, P. NIH consensus panel urges antimicrobials for ulcer patients, skeptics concur with caveats. JAMA 271, 808-809 (1994).
9. Graham, D. Y., Lu, H. & Yamaoka, Y. Y. Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond. Drugs 68, 725-736 (2008).
10. Warren, J. R. & Marshall, B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 321, 1273-1275 (1983).
11. Marshall, B. J. & Warren, J. R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1, 1311-1315 (1984).
12. Malfertheiner, P., Chan, F. K. & McColl, K. E. Peptic ulcer disease. Lancet 374, 1449-1461 (2009).
13. Amieva, M. R. & El-Omar, E. M. Host-bacterial interactions in Helicobacter pylori infection. Gastroenterology 134, 306-323 (2008).
14. Wotherspoon, A. C., Ortiz-Hidalgo, C., Falzon, M. R. & Isaacson, P. G. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 338, 1175-1176 (1991).
15. Ruskoné-Fourmestraux, A. et al. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 60, 747-758 (2011).
16. Nakamura, S. et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut 61, 507-513 (2012).
17. Hatakeyama, M. Helicobacter pylori and gastric carcinogenesis. J. Gastroenterol. 44, 239-248 (2009).
18. Correia, M., Machado, J. C. & Ristimäki, A. Basic aspects of gastric cancer. Helicobacter 14 (Suppl. 1), 36-40 (2009).
19. Mizuno, S. et al. Prescreening of a high-risk group for gastric cancer by serologically determined Helicobacter pylori infection and atrophic gastritis. Dig. Dis. Sci. 55, 3132-3137 (2010).
20. Vakil, N. & Megraud, F. Eradication therapy for Helicobacter pylori. Gastroenterology 133, 985-1001 (2007).
21. Tepes, B., O'Connor, A., Gisbert, J. P. & O'Morain, C. Treatment of Helicobacter pylori infection. Helicobacter 17 (Suppl. 1), 36-42 (2012).
22. Malfertheiner, P. et al. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 61, 646-664 (2012).
23. Blaser, M. J. Equilibria of humans and our indigenous microbiota affecting asthma. Proc. Am. Thorac. Soc. 9, 69-71 (2012).
24. Kobayashi, I. et al. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J. Clin. Microbiol. 45, 4006-4010 (2007).
25. Ang, T. L. et al. Is there still a role for empiric first-line triple therapy using proton pump inhibitor, amoxicillin and clarithromycin for Helicobacter pylori infection in Singapore? Results of a time trend analysis. J. Dig. Dis. 14, 100-104 (2013).
26. Liou, J. M. et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 381, 205-213 (2013).
27. Graham, D. Y. & Rimbara, E. Understanding and appreciating sequential therapy for Helicobacter pylori eradication. J. Clin. Gastroenterol. 45, 309-313 (2011).
28. Rimbara, E., Fischbach, L. A. & Graham, D. Y. Optimal therapy for Helicobacter pylori infections. Nat. Rev. Gastroenterol. Hepatol. 8, 79 (2011).
29. Vécsei, A. et al. Stool polymerase chain reaction for Helicobacter pylori detection and clarithromycin susceptibility testing in children. Clin. Gastroenterol. Hepatol. 8, 309-312 (2010).
30. Zhang, S., Moise, L. & Moss, S. F. H. pylori vaccines: why we still don't have any. Hum. Vaccin. 7, 1153-1157 (2011).
31. Moss, S. F. et al. HelicoVax: epitope-based therapeutic Helicobacter pylori vaccination in a mouse model. Vaccine 29, 2085-2091 (2011).
32. Kabir, S. The current status of Helicobacter pylori vaccines: a review. Helicobacter 12, 89-102 (2007).
33. Del Giudice, G., Malfertheiner, P. & Rappuoli, R. Development of vaccines against Helicobacter pylori. Expert Rev. Vaccines 8, 1037-1049 (2009).
34. Aebischer, T. et al. Correlation of T cell response and bacterial clearance in human volunteers challenged with Helicobacter pylori revealed by randomised controlled vaccination with Ty21a-based Salmonella vaccines. Gut 57, 1065-1072 (2008).
35. Malfertheiner, P. et al. Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study. Gastroenterology 135, 787-795 (2008).
36. Bühling, A., Radun, D., Muller, W. A. & Malfertheiner, P. Influence of anti-Helicobacter triple therapy with metronidazole, omeprazole and clarithromycin on intestinal microflora. Aliment. Pharmacol. Ther. 15, 1445-1452 (2001).
37. Lee, Y. Y., Mahendra Raj, S. & Graham, D. Y. Helicobacter pylori infection-a boon or a bane: lessons from studies in a low-prevalence population. Helicobacter http:///dx.doi.org/10.1111/hel.12058.
38. Liu, Y., Akiyama, J. & Graham, D. Y. Current understandings of Helicobacter pylori, peptic ulcer and gastroesophageal reflux disease. Minerva Gastroenterol. Dietol. 52, 235-248 (2006).
39. Bik, E. M. et al. Molecular analysis of the bacterial microbiota in the human stomach. Proc. Natl Acad. Sci. USA 103, 732-737 (2006).
40. Osaki, T. et al. Comparative analysis of gastric bacterial microbiota in Mongolian gerbils after long-term infection with H. pylori. Microb. Pathog. 53, 12-18 (2012).
41. Graessler, J. et al. Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters. J. Pharmacogenomics http://dx.doi.org/10.1038/tpj.2012.43.
42. Jakobsson, H. et al. Macrolide resistance in the normal microbiota after Helicobacter pylori treatment. Scand. J. Infect. Dis. 39, 757-763 (2007).
43. Thirumurthi, S. & Graham, D. Y. Helicobacter pylori infection in India from a western perspective. Indian J. Med. Res. 136, 549-562 (2012).
44. Fock, K. M. et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J. Gastroenterol. Hepatol. 24, 1587-1600 (2009).
45. Strugatsky, D. et al. Structure of the proton-gated urea channel from the gastric pathogen Helicobacter pylori. Nature 493, 255-258 (2013).